Injury to CNS involves an initial microgliosis followed by a more persistent astrogliosis. Ideally, both populations might come back to their resting phenotypes once the lesion is repaired and neuroinflammation is resolved. Spinal cord injuries usually imply an abnormally persistent glial activation, which contributes to the detrimental effects of the secondary phase, such as hyperexcitability and neuropathic pain. Our treatment with GB is aimed to trigger the initial activation of microglia in order to better scavenge all the myelin and cell debris just after the contusion. Indeed, GB promotes a minor infiltration of macrophage and microglia, but with an enhanced phagocytic phenotype. This results as a better functional performance, better tissular preservation, but also a worsening in neuropathic pain signs.